hotspot -WSS

hotspot

author：knowledge 2025-09-29 22:48:36 - browse：59

Each COVID-19 vaccine vial from various companies is placed on individual rectangular backgrounds. Pfizer-BioNTech is positioned in the middle on a purple block adorned with two glitter star stickers, Moderna is on the top right on a red block, Janssen is on the bottom right on a blue block, and AstraZeneca is on the left on a red block. — Illustration: Christine Kao/STAT; Photos: Getty

It’s been four years since Covid-19 emerged, igniting a pandemic that killed millions of people and brought the world to its knees. A key factor in taming the pandemic was the creation of effective vaccines, which have saved millions of lives.

You’d think developing a successful vaccine would be an unmitigated win, from a financial perspective. And, indeed, for Pfizer and its partner BioNTech, as well as for Moderna — whose vaccines were the most widely used in the United States and much of the world — the revenues generated were absolutely staggering. But investors have shrugged at those sales as gains that will not be repeated.

Total sales of the Pfizer/BioNTech vaccine surpassed $80 billion, and more than 400 million doses of the shot and subsequent boosters have been administered in the U.S. alone. But the company’s stock price fell 32% over the past five years. Meanwhile, AstraZeneca, which told STAT it has not booked sales from its vaccine since last April and does not expect future sales, has seen its share price rise 64%. Merck, which saw its vaccine efforts fail twice, is up 56%.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： George Santos makes 1st court appearance after pleading not guilty to 13 counts
Next article： Testing GLP

WSS

Mass General Brigham physicians react to latest merger step

Biotech investment managers search for lucrative opportunities

Medicare Advantage 2025 payments will dip, Biden administration says

Biotech investment managers search for lucrative opportunities

Medical devices makers are asking for forgiveness, not permission

UnitedHealth, in a surprise, takes aim at Steward’s physician group

focus

hotspot

knowledge

Trump demands the U.S. pay no more for drugs than other countries … again

Readout Newsletter: Illumina, CRISPR, Regeneron

Affirmative action in medical school literally saved lives

Alzheimer's risk factor APOE4 may be a distinct form of the disease

Medicare details structure of new drug price negotiation program

U.K. officials, researchers try to ease path for bespoke genetic treatments

Alkermes shareholders re

Gut bacteria may contribute to kidney autoimmunity, study finds

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

UnitedHealth, in a surprise, takes aim at Steward’s physician group

leisure time

Mass General Brigham physicians react to latest merger step

U.K. officials, researchers try to ease path for bespoke genetic treatments

Scientific mystery highlights the blind spots in genomics databases

Study: Black kids more likely to die after surgery than white kids

UnitedHealth, in a surprise, takes aim at Steward’s physician group

Medicare Advantage insurers pressure Biden for bigger payments

leisure time

hotspot

leisure time

focus